Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

CellaVision, Audiocast with teleconference, Q1'24

By Inderes4/25/2024, 9:00 AM
CellaVision

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Simon Østergaard
00:02 - 18:01

Thank you very much for the introduction. And thank you very much to everyone out there who has taken the time and interest to dial in to hear our quarterly report, the first here in 2024. I have our CFO, Magnus, with me. And, we'll be happy to present and also to answer any questions you may have subsequently. But let's dive right into it. So, in the first quarter this year, we ended our revenues at 170 million SEK, which represents an organic growth of 22%. Essentially, there was no currency effect. EBITDA margin wise, we landed the result at 29%. So, it's a little bit lower than our corporate target. And I'll get back to the main driver, which revolves around our gross margin. If we take the highlight of our quarter, we believe this represents a solid start to the year. We have, in fact, growth from all regions. Both number wise, revenue wise, but also the conversations we've had interfacing with end users and so forth. We have a strong belief that our traction for all our solutions is really compelling. And that actually goes beyond just one region; it is also represented across the different markets. Financially, our position is in a strong position. And I will elaborate on our cash flow. But cash flow and balance sheet wise, we're in a very solid position. And furthermore, I also want to emphasize that we are working hard on progressing our strategic direction. And we are really progressing there. Finally, one of the levers for our strategic pillar around the globalization of our reagent business is going according to plan. And we now have our new factory up and running in Bordeaux. We had a little bit of that and adjustments to our plan for the bone marrow and the specialty analysis strategic pillar. So the specialty analysis is where we're looking at new diseases to diagnose with sophisticated AI and tailor-made reagents. For the bone marrow projects. We do have an adjustment around our assumption to the registration. Basically, it was assumed to be a class A product initially, and we don't believe that's the path to take, which has introduced a longer time for registration as we need to engage and document in a way that has to be, we have to engage with our notified body to a larger extent, and that adds delays. So we believe that our product will be launched next year in 2025. Furthermore, a key message which was actually happening in Q1. But we took the liberty to report that just after signing at the last annual report in the beginning of February. But we did in this quarter sign a strategic alliance agreement with Sysmex Corporation in this quarter. So we have formalized our mutual commitments until 2038 around our partnerships. And I can talk a little bit about that as we proceed. But we have really been trying to unfold and work on our objectives throughout this, our joint collaboration objectives, throughout this quarter. With that, I suggest we take the next slide and try to unfold the P&L. So I saw pretty strong growth, organically. Of course, also fair to say, up against we compare in Q1 last year. I think the weak spot in our results this quarter is actually not on the revenue. It's on the gross margin. We had a 66% gross margin. And that is really, there are a few drivers for that. It's the product mix. So the combination of the offerings, the different components was not in our favor from a gross margin perspective. We were low on software, which hits us, also against actually, even though the revenue last year in the comparison was lower, the software component was relatively high. And so we're a little bit hit on that. Material cost prices have gone up as well. And we have not implemented, only to a very little degree, our price increases. That's another thing that this represents. On the cost side, the full year raise of supplies and materials. However, we have no adjustments on the pricing. So that is also why the gross margin is a little bit lower than usual on the operating expenses. I have to say, we're in full control. We did some restructuring at the end of last year, which is coming into effect. So we've managed to keep our sales and marketing costs totally constant, even though there are cost increases also for some of these services, etc. But that has remained in total control. And we are only increasing our admin and our R&D with a little bit of consultancy, really, mind you. So it's pretty much kept constant according to our plan. Which means that our EBITDA of 49 million is obviously much better due to the higher revenue. However, our EBITDA margin of 29% really comes below our target of 30% or more. And that is due to the gross margin as I just alluded to. We are continuing our path of investing in R&D to support our power-focused strategy, which is also pretty much in line with our plan here. And we're also capitalizing our R&D costs. So we did capitalize about 2 million more than last year. So we ended around 15 million. Looking at the cash flow, we are proud to say it's a pretty strong cash flow from operating activities. We landed at 50 million before we do the working capital adjustment. And when we do the working capital adjustment, we added another 21 million. So we landed our operating cash flow at 71 million. On the working capital, we've been working very actively on continuing the journey of reducing our inventory that has given us some contribution, sort of in line with previous quarters, maybe 20% of the working capital delta there, and then 80% actually comes from the accounts receivable, where we have gotten the payment from Q4 as well. So, cash flow-wise, it was solid. On the investment side, I talked about the capitalized development, but also, I think it's fair to say that we completed our manufacturing expansion, as I also mentioned in the beginning, and that actually brings seven to eight million less of investments into the equation, which also translates into a strong total cash flow of 44 million versus a negative result in our company. So balance sheet-wise, this actually results in a cash and cash equivalents of 167 million SEK today, which is in comparison to 93 million a year ago. And we have driven down our long-term debt. So it's about 25 million as of now. And so we are in a very strong position from a balance sheet perspective, cash flow perspective. Let's go to the next slide. So let's take a look at the regional highlights. And so across the board across the three regions as you see here, very similar growth from 21 to 23%, which translated into 22% overall. Of top line growth and organic growth. Essentially, I'm proud to see that there is really traction in Americas for, in fact, our instruments are growing both large and small. We had a particularly very good quarter on the small ones. So I would say high double-digit growth, very high double-digit growth for the DC-1s. So again, we are building our strategy of building ecosystems in the lab in the hematology lab environment. And that is also about capturing the blood work in the smaller labs. And we are pursuing that. So we are selling DC-1s for the small lab segment. However, for some of these regions in the US, the situation is that we are selling into regions that may already be running in the large labs, which means that the need for software is a little bit lower. So what we've seen is that at least a main hypothesis that we are seeing a little bit lower software as a result of that. So our software sales this quarter. When we talk about product mix has been weaker and we are up against a relatively hard comparison from last year on the software side. Um, so this is one of the drivers for the lower gross margin. Other than that, we're ramping up sales in Latin America. Also on the decline, we see appetite for the CellaVision® DC-1, including our pre-analytical workflow components. So that's very interesting for us to drive growth in that region. And also, we've gotten good feedback from the feature that we have launched in the US in terms of federal audits, which is able to detect platelet clumps in the blood smear. So that's another assisting digital enabling point for the clinical community that has been well received in EMEA. We ended up with the instrument sales of 27%. In total, sales increased to 79 million for the region, with 27% growth on the instrument side. And I'm also super pleased to see that that was entailed both from our large instruments. But also, we have significant growth in the small segment. So it is promising, specifically if we zoom in on the UK, where we've traditionally had a bit of a challenge getting adoption there. We're really seeing some interesting moves there. And also in the Middle East, where of course, Saudi Arabia is probably the largest country or largest market in that region. I'll talk a little bit more about regions later. For APAC, yeah. Here, we are super pleased to see that our revenue is actually continuing in China. But actually, we are also seeing growth in Japan. We have had a bit of an inventory situation in Japan, but we are out of the woods. So we're starting to see orders coming from Japan as well. And then, given the alliance with Sysmex, we also are seeing some very good conversations on getting closer to how we can penetrate and adopt digital morphology in that region, which is a bit more immature as opposed to EMEA and Americas. So all in all, also positive signs from India. If we go to the sales per product group and slide the sales numbers per product family. The first one is the instruments. So here we had on the instrument side a total of 91 million versus 66 in the quarter. So it is significant growth. But we also had a bit of an instrument inventory adjustment in the comparative quarter. That's fair to say. I did mention the significant CellaVision® DC-1 adoption in America. Very much so for Europe, and again, we are pleased to see that the DIFF-Line™, I'm aware we've been talking about the launch of DIFF-Line™ quarters back, but bear in mind that for us, that's our launch. That's when the products are ready and then our partners actually bring it out and test it in the labs, get the feedback from the clinics. So there's a time delay from when we sort of launch it as a solution. And then, our partners really bring it out, launch it, and push the marketing campaign. But that is starting to happen now, in the US as well, with traction and opportunities in Latin America. So, exciting times for us. On the reagent side, just continuing a steady recurring revenue growth there with 20% out of EMEA. And so we increased to 36 million. That really sort of makes us comfortable in terms of the significant investment we undertook throughout 2023, where we built a new factory, and we are ready to entertain this double-digit continuous growth figures we see from our hematology fraction of the related business, software again, yes, up against the trough compared. But no doubt, it was lower than expected. So we're sort of looking into that. And it was weak. One of the drivers is the networks. But let's see what variability was present for the quarter versus a general drive of software. Yeah, that is probably good. So if we go to the key takeaways, and I just give you the brief version here, again, a strong start to the year. And as you saw, really consistent growth across all regions. We acknowledge a weak gross margin. We are in full control, opex wise. And we've done some adjustments to really set us up for success with this new innovation and commercial setup with Sysmex. But we're in full control. Coming back to the gross margin, product mix, price. Price increases that are not really implemented to a great extent at all. They'll impact us, and then everything, as I said, we translate our P&L and also our working capital management into a very strong cash flow for the company. So, we've been working with enhanced collaboration with our key distribution partners, and I would pair that with our strategic alliance agreement with Sysmex. We've really started to get into the weeds of understanding the individual markets. Making new connections with our colleagues at Sysmex and starting to interpret what it really takes in terms of training and focus on what is needed at the end. User labs out there to pursue the mission of adopting digital cell morphology as part of the bloodline, but also to innovate new, sophisticated solutions to protect our leadership within hematology. And then again, I want to emphasize that one of the levers for the first specialty application is the bone marrow. We are confident with the adjustments we've made in the product. We are running the clinical trials. However, we will spend a month on the alignment and the dialogue with our notified body. So, we will have the results, and we expect to see CE Mark in 2025. Uh, very limited financial impact from that. Um, because all the programs have been budgeted for and it's a slow ramp-up, but it will be a module that will be used on the DC-1. So we have time also to build a solid launch strategy. But for now, we are focusing on completing our clinical studies on the module. So with that, I think we should go to questions and answers if there are any around. So please open the floor for any questions you may have.

Unknown
18:04 - 18:27

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ulrich Ratner from Carnegie. Please go ahead.

Unknown
18:28 - 19:15

Great. Thank you very much. And good day, Simon. And minus a few questions on my end related to topics you already highlighted, starting off with bone marrow and the slight delay here in CE. Mark. Uh, if you can give us some more clarification when you are expected to receive approval in 2025. And in addition, as you mentioned, it's a small financial impact since it will be a gradual step up in sales. But when are we to expect some meaningful contribution from bone marrow? Is that possible in the later 2025, or is that more feasible in 2026?

Simon Østergaard
19:17 - 20:58

I think, um, when we talk about things and how we work, when we talk about the launch of a product like bone marrow, I think, um, when you use the word 'meaningful' as that, that's, uh, I interpret that as something that gives significant revenues. That is a few years out. Um, because I do believe that what will happen is that we will have the bone marrow module and there needs to be a level of comfort with the product because it will assist the manual interpretation. Um, so I think people will start to use it. There will be endorsement, but typically for these types of modules, it will take some years to make meaningful revenues. However, I think we are set up perfectly for a good launch because we already have the customer base who will require this. This will be primarily the large labs where they have adopted the concept of digital cytology. So I'm positive when we have, you know, concluded on the clinical trials and the documentation, pretty positive that we will get out there. Um, but the revenue, we don't expect like a hockey stick; there is always a certain delay. The purchasing cycles will be less because it's not a total bloodline. It's the DC-1 and the software. So I think the investment in this tool here will be less of a barrier, which will speak in favor of increasing the slope on the adoption line. Great.

Unknown
20:58 - 21:18

And a follow-up question on that, since you mentioned it won't follow the same purchasing pattern as a complete bloodline, which is replaced every 9 to 11 years. So what's your interpretation on how this will be implemented or the sales cycle of this new system?

Simon Østergaard
21:20 - 22:11

Yeah, I'd say it's, um. It's probably a little, uh, early, because we only have limited feedback from the sites that we work with who are very, very interested in this because it solves a huge clinical, um, question, but or clinical needs. But, um, but I see no reason why we shouldn't, over the course of a five-year period, sort of really have a high adoption of this in the labs that are already running digital. Some of it is plugged right into the ecosystem. It's just more content. But again, the DC-1 will now be also targeted for the large labs and not just the small labs, which is where we are seeing significant adoption these days. So it is a revenue opportunity, uh, for us instrument and software-wise for the last lab.

Unknown
22:13 - 22:46

Great. And since you mentioned DC-1 and. If I may interpret this correctly, you sound more optimistic than before regarding the DC-1 development in Europe. Has anything changed the dynamics, the customers? You have targeted your efforts in Europe? Or is there any other factor that plays into this and your optimistic outlook?

Simon Østergaard
22:48 - 24:02

Yeah. I mean, I would say, you know, black and white, I can see that our growth rates are pretty sort of very healthy double-digit in Europe. Um, for the DC-1. So that makes me. I'm hopeful about this, then I know that every quarter there can be some, sometimes as little, sometimes as high. But actually, that's sort of proof of a really an appetite to also in countries where digital hematology has not been adopted that. Well there I see the we see the DC-1 as a really good tool. It's affordable but it really demonstrates in the environment where you're not, you know, you don't necessarily have that many trained medical technologists. So we are starting to see some really positive appetite to start adopting digital hematology via the DC-1. So that's really where I see the change. And then no secret, we, of course, our alliance with Sysmex endorses and opens doors for new teams where we can have a closer conversation so we get wiser on how we help position this together with Sysmex.

Unknown
24:05 - 24:52

Great. Um, and last question on my end, and you talked about this. It really looks like you've entered a phase of very strict cost control. Um, what is to be expected here in the coming quarters? Are you in the mode here when growth returns, that you will start to invest again? And I know that you have this collaboration with Sysmex, and this opens a lot of doors. And I'm guessing there is an ambition on your end to expand on the sales and marketing side of things as well. So where are we at in terms of managing costs versus growth here?

Simon Østergaard
24:53 - 27:21

Yeah. No, I think also given the inventory adjustments we were faced with throughout 2020, end of 2022 and throughout 2023, we wanted to be responsible, since we had less control of our top line, to really control our cost base so we could deliver profits from the company. At the same time, we had a drive for being efficient, and that's what we implemented in autumn. On the sales and marketing side, making sure that our setup is tuned. Also, as we were seeing the light at the end of the tunnel with the alliance, we had to set us up optimally. But that's not to say that we're not investing in sales and marketing. We are doing that in terms of tools, training. But we are also seeing opportunities where it makes sense to invest people in markets where we can fuel and accelerate the adoption of digital. So we have a few countries on the map. And so, we're not hesitant to invest, but we're investing our money very wisely with a reasonable rate of return. That's really how you should look at it. So there's been a little bit of a cleanup. This is a bit too harsh of a word. But there has been an optimization going on in the R&D expense. We spent 21% of our revenue this quarter on R&D and the power of focused strategy with large labs, small labs, reagents, specialties, and also the new areas that strategy we are pursuing that, as we have articulated previously, we have funded our R&D, also our next-gen program, etc. The specialty, fueled by bone marrow and others, has been fueled. So we are pursuing that. There is a question mark around, we are seeing so promising results from our FPM technology. So there is a conversation on how to and how much to invest. That is a conversation for the future. But you should know that we are really seeing a positive maturation of the technology. So at some point we are having serious conversations whether we should ramp up our investments to mature that, also in collaboration with potential partners, as we alluded to in the Q4 report.

Unknown
27:22 - 27:27

Great. That is very helpful. Thank you very much, Simon. And I'll get back into the queue.

Simon Østergaard
27:28 - 27:30

No, thanks. All right.

Unknown
27:34 - 27:39

The next question comes from Ludwig, from Lundgren. Please go ahead.

Simon
27:41 - 28:08

Yes. Hi, Simon and Magnus. Thanks for taking my questions. So first, I want to dig in a bit to the gross margins, which was down a bit compared to last year. So you say it's mainly a sales mix, but also mention, I think, in the report that it could be offset by the price increases somewhat. So I wonder, yeah, how much of an effect this can have, for example, for Q2 and as we move through 2024.

Simon Østergaard
28:09 - 28:14

Yes, you can elaborate on it. Yeah, I can.

Magnus
28:14 - 29:00

Elaborate a bit on that. It's correct that we saw some negative effects from the price mix. Um, the product mix. And also, if you look at the price increases, the way we roll in price increases to offset inflation pressure, let's say the way we roll those in this year versus last year, is that there is a slight delay when it comes to negotiations, they've dragged out a bit longer in time. So last year, we saw some effect in Q1 and most of the effect in Q2, and this year, we're a little bit later in that process. So there is not so much effect at all actually in Q1 for that one. And we expect to start seeing that from Q2 and onwards.

Simon
29:03 - 29:29

Okay. Great. That's very helpful. Um, and then maybe a bit on the strategic partnership. So we have seen Sysmex rolling out the XN series in EMEA. In mid-2023, I think it started. And also, we see you delivering quite good instrument sales in EMEA. Is this connected, or is it not really driven by replacement?

Simon Østergaard
29:32 - 30:02

It is somewhat connected because they also have in some countries really high attachment rates. So we are certainly partnering on that side. Definitely. And it is the XN that comes into play here. But I think it's not just replacing. It's also a cycle thing. And for the labs where they actually purchase a new blood line here. So this makes our marketing the XN. And that's where our DC-1 follows suit.

Simon
30:05 - 30:19

All right. Great. So. And then also, with this new partnership, could this maybe enable you to be able to push reagents in new geographies, or is this mainly focused in relation to the instrument side?

Simon Østergaard
30:21 - 31:03

No, this is more, as you allude or sort of implicitly say in the question here, that this is a global ambition of leading in hematology. So certainly, we see this as an opportunity to roll out and pursue our strategic pillar of globalizing reagents. No doubt that we have a strong footprint in India, but we have certain ambitions around APAC where we've started to launch, but certainly also around the US. So we see this partnership as an ally for globalization of reagents on top. We really want to bring the best workflow out in hematology through this alliance. And we think that's the opportunity we have at hand collectively.

Simon
31:05 - 31:13

Right. And, is it possible to get some type of timeline for when we could see a potential step up in, for example, Americas or APAC?

Simon Østergaard
31:15 - 32:02

Now in APAC, we can be explicit on that. We are seeing that we are starting to get revenues from multiple countries, smaller markets where they start to position the brand as things, which is really helpful. We've not seen significant revenues from the large countries like China. So that's a bit more long term. But this is something we are really working on. We think that's a great opportunity. And then I will be more explicit on the US when appropriate. But certainly, it's an ambition of ours. And we are on the internal lines working on the prerequisites for that to happen. And here I just want to say that we are progressing.

Simon
32:04 - 32:08

Perfect. Very helpful. Thanks a lot for taking my questions.

Simon Østergaard
32:09 - 32:10

No, it's a question.

Unknown
32:13 - 32:20

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Simon Østergaard
32:23 - 33:12

All right. Again, thanks to everyone out there for listening in on our Q1 call. I said, strong start to the year. I just want to close by also thanking my colleagues for that and also our partners and not the least our Sysmex colleagues for all the communication and engagement we've seen throughout this quarter. I just want to emphasize that we have our annual general meeting being held here in Lund, Sweden, on the 3rd of May in a week. So we are looking forward to seeing any shareholders at that meeting. And so thanks a lot. And, we'll get back and continue to push the business. So thanks a lot. Have a great day.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…